View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
April 27, 2020

ViiV commits £3m to research and mitigate impact of Covid-19 on HIV patients

By Allie Nawrat

HIV-speciality company ViiV Healthcare has created a £3m global fund, known as the Global HIV and Covid-19 Emergency Response Fund, to research medical impact of Covid-19 on people living with HIV. It will also support necessary local initiatives and organisations that are struggling to support the HIV community in the pandemic.

The company has pledged £1.5m to research projects studying the impact on people living with HIV. While the remaining £1.5m will be dedicated to a Community Emergency Response Fund.

ViiV chief medical officer Harmony Garges commented: “Because Covid-19 is caused by a novel virus, we don’t have scientific data to answer some of the important questions that are being raised by people living with HIV and their physicians.

Does HIV put a person at greater risk of getting COVID-19? Are people living with HIV more at risk of severe infection? Is the pandemic preventing people with HIV from seeing their healthcare providers and getting the treatment and care they need?

“The HIV community at large has asked us for help to immediately start studying these issues and the Global HIV and Covid-19 Emergency Response Fund has been created to support their efforts.”

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU